Abstract
Herpes simplex virus type-1 (HSV-1) has been used for gene delivery in the nervous system for the treatment of brain tumors and other neurological diseases. In most protocols, recombinant viruses containing the gene of interest are directly injected into the brain. Since many people harbor latent wild-type HSV-1 virus in sensory ganglia and other regions of the nervous system, there is a potential risk that the injected recombinant virus may reactivate the latent wild-type virus to cause severe encephalitis. The present study used two rat latent infection models to evaluate this risk. Adult rats were infected with wild-type kos by cornea scarification or by intracerebral injection, and after the establishment of latency, the ICP6(−) strain hrR3 was injected intracerebrally. In the control group, the latent virus was reactivated by treatment of cadmium sulfate. Viral shedding from tears was detected by incubation with Vero cells, and the trigeminal ganglia, cortical tissue and the eyes were collected to detect reactivated wild-type virus by RT-PCR. Our results showed that while the reactivated wild-type virus was readily detectable in the cadmium–sulfate-treated animals, intracerebrally infected hrR3 did not reactivate the latent virus in either the corneal model or the cerebral model. These results indicate that intracranial injection of partially defective recombinant virus may bear little risk of reactivating latent wild-type virus harbored in the sensory ganglia or the brain in our animal model.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wang, Q., Guo, J. & Jia, W. Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1. Gene Ther 4, 1300–1304 (1997). https://doi.org/10.1038/sj.gt.3300535
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300535
Keywords
This article is cited by
-
HSV-1’s contribution as a vector for gene therapy
Nature Biotechnology (2022)
-
Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1
Gene Therapy (2021)
-
Nasal application of HSV encoding human preproenkephalin blocks craniofacial pain in a rat model of traumatic brain injury
Gene Therapy (2017)
-
Herpes simplex virus 1 (HSV-1) for cancer treatment
Cancer Gene Therapy (2006)
-
Oncolytic viral therapies – the clinical experience
Oncogene (2005)